

Additional Resources

Table (I): Cardiac burden of less common diseases with more severe cardiac affection.

Disease	Prevalence	Percentage Of Heart Affection	Risk Of Cardiac Death
sarcoidosis	4.7– 64 per 100,000 ¹	19.5-28% Occult cardiac involvement ²	77 to 85% of deaths ²
Amyloidosis	8 to 12/ million person-years ³	50–60% ⁴	< 1-year median survival with cardiomyopathy ⁵
Systemic Sclerosis	7-489/million ⁶	15% to 35% ⁷	27.2% ⁸
Friedreich's ataxia	1:50,000 live births ⁹	Nearly all patients develop cardiomyopathy ⁹	59% ¹⁰
Duchenne muscular dystrophy	15.9-19.5/100,000 births. ¹¹	27-57% ¹¹	Median survival rate = 40.9 years (for those born after 1970) ¹²
Hypereosinophilic syndrome	0.036 per 100,000 ¹³	40% ¹⁴	-

Table (II): Further uses of STE in systemic diseases

Toxic cardiomyopathy	preeclampsia ¹⁵ methamphetamine abuse ¹⁶ carbon monoxide poisoning ¹⁷
Metabolic and endocrine diseases	cirrhotic cardiomyopathy ^{18,19} polycystic ovary syndrome ²⁰
Genetic diseases	Duchene's disease ^{21,22} Friedreich's ataxia ²³ Hypereosinophilic syndrome ²⁴
Infective diseases	Chagas disease ^{25,26}

References

1. E. Perez I, J. Garcia M, C. Taub C. Multimodality Imaging in Cardiac Sarcoidosis: Is There a Winner? *Curr Cardiol Rev.* 2016;12(1):3-11. doi:10.2174/1573403x11666150318110406
2. Lynch JP, Hwang J, Bradfield J, Fishbein M, Shivkumar K, Tung R. Cardiac involvement in sarcoidosis: Evolving concepts in diagnosis and treatment. *Semin Respir Crit Care Med.* 2014;35(3):372-390. doi:10.1055/s-0034-1376889
3. Bayliss M, McCausland KL, Guthrie SD, White MK. The burden of amyloid light chain amyloidosis on health-related quality of life. *Orphanet J Rare Dis.* 2017;12(1):1-10. doi:10.1186/s13023-016-0564-2
4. Karafiatova L, Pika T. Amyloid cardiomyopathy. *Biomed Pap.* 2017;161(2):117-127. doi:10.5507/bp.2017.001
5. Brownrigg J, Lorenzini M, Lumley M, Elliott P. Diagnostic performance of imaging investigations in detecting and differentiating cardiac amyloidosis: a systematic review and meta-analysis. *ESC Hear Fail.* 2019;6(5):1041-1051. doi:10.1002/ehf2.12511
6. Chiffot H, Fautrel B, Sordet C, Chatelus E, Sibilia J. Incidence and Prevalence of Systemic Sclerosis: A Systematic Literature Review. *Semin Arthritis Rheum.* 2008;37(4):223-235. doi:10.1016/j.semarthrit.2007.05.003
7. Kahan A, Coghlan G, McLaughlin V. Cardiac complications of systemic sclerosis. *Rheumatology (Oxford).* 2009;48 Suppl 3:iii45-8. doi:10.1093/rheumatology/kep110
8. Wangkaew S, Prasertwitayakij N, Phrommintikul A, Puntana S, Euathrongchit J. Causes of death, survival and risk factors of mortality in Thai patients with early systemic sclerosis: inception cohort study. *Rheumatol Int.* 2017;37(12):2087-2094. doi:10.1007/s00296-017-3846-7
9. Hanson E, Sheldon M, Pacheco B, Alkubeysi M, Raizada V. Heart disease in Friedreich's ataxia. *World J Cardiol.* 2019;11(1):1-12. doi:10.4330/wjc.v11.i1.1
10. Kearney M, Orrell RW, Fahey M, Brassington R, Pandolfo M. Pharmacological treatments for Friedreich ataxia. *Cochrane Database Syst Rev.* 2016;2016(8). doi:10.1002/14651858.CD007791.pub4
11. Ryder S, Leadley RM, Armstrong N, et al. The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: An evidence review. *Orphanet J Rare Dis.* 2017;12(1):79. doi:10.1186/s13023-017-0631-3
12. Kieny P, Chollet S, Delalande P, et al. Evolution of life expectancy of patients with Duchenne muscular dystrophy at AFM Yolaine de Kepper centre between 1981 and 2011. *Ann Phys Rehabil Med.* 2013;56(6):443-454. doi:10.1016/j.rehab.2013.06.002
13. Gotlib J. World Health Organization-defined eosinophilic disorders: 2015 update on diagnosis, risk stratification, and management. *Am J Hematol.* 2015;90(11):1077-1089. doi:10.1002/ajh.24196
14. Sen T, Gungor O, Akpınar I, Cetin M, Tufekcioglu O, Golbasi Z. Cardiac involvement in hypereosinophilic syndrome. *Texas Hear Inst J.* 2009;36(6):628-629.
15. Shahul S, Rhee J, Hacker MR, et al. Subclinical left ventricular dysfunction in preeclamptic women with preserved left ventricular ejection fraction: A 2D speckle-tracking imaging study. *Circ Cardiovasc Imaging.* 2012;5(6):734-739. doi:10.1161/CIRCIMAGING.112.973818
16. Zhang LJ, Chen KQ, Shi YY, Qiao XL, Wang LY, Zheng XZ. Findings on 3D speckle tracking echocardiography in asymptomatic methamphetamine abusers. *Int J Cardiovasc Imaging.* 2018;34(10):1589-1593. doi:10.1007/s10554-018-1381-6
17. Saraçoğlu E, Vuruşkan E, Kılıç S, et al. Predicting Cardiotoxic Effects of Carbon Monoxide Poisoning Using Speckle Tracking Echocardiography. *Cardiovasc Toxicol.* 2018;18(2):175-183. doi:10.1007/s12012-017-9428-9
18. Sampaio F, Pimenta J, Bettencourt N, et al. Left atrial function is impaired in cirrhosis: A speckle tracking echocardiographic study. *Hepatol Int.* 2014;8(1):146-153. doi:10.1007/s12072-013-9469-5
19. Wong F. Speckle tracking echocardiography in cirrhosis: Is it ready for prime time? *Hepatol Int.* 2014;8(1):10-13. doi:10.1007/s12072-013-9513-5
20. Erdoğan E, Akkaya M, Bacaksız A, et al. Polikistik over sendromlu hastalarda subklinik sol ventrikül disfonksiyonu: Gözlemsel bir çalışma. *Anadolu Kardiyol Derg.* 2013;13(8):784-790. doi:10.5152/akd.2013.196

21. Mertens L, Ganame J, Claus P, et al. Early Regional Myocardial Dysfunction in Young Patients With Duchenne Muscular Dystrophy. *J Am Soc Echocardiogr*. 2008;21(9):1049-1054. doi:10.1016/j.echo.2008.03.001
22. A. Taqatqa, J. Bokowski, M. Al-Kubaisi et Al., "The Use of Speckle Tracking Echocardiography for Early Detection of Myocardial Dysfunction in Patients with Duchenne Muscular Dystrophy," *Pediatric Cardiology*, Vol. 37, No. 8, Pp. 1422–1428, 2016.
23. G. Buyse, L. Mertens, G. Di Salvo et al., "Idebenone treatment in Friedreich's ataxia: Neurological, cardiac, and biochemical monitoring," *Neurology*, vol.60, no.10, pp. 1679–1681, 2003.
24. Nemes A, Kormányos Á, Domsik P, et al. Left ventricular rotational mechanics in hypereosinophilic syndrome—Analysis from the three-dimensional speckle-tracking echocardiographic MAGYAR-Path Study. *Echocardiography*. 2019;36(11):2064-2069. doi:10.1111/echo.14517
25. Nunes MCP, Badano LP, Marin-Neto JA, et al. Multimodality imaging evaluation of Chagas disease: an expert consensus of Brazilian Cardiovascular Imaging Department (DIC) and the European Association of Cardiovascular Imaging (EACVI). *Eur Heart J Cardiovasc Imaging*. 2018;19(4):1-16. doi:10.1093/ehjci/jex154
26. Macedo CT, Larocca TF, Noya-Rabelo M, et al. Assessment of speckle tracking strain predictive value for myocardial fibrosis in subjects with Chagas disease. *IJC Hear Vasc*. 2015;8:75-80. doi:10.1016/j.ijcha.2015.05.007